AdAlta Ltd.ASX: 1AD

EW-001 Orphan Drug Designation, pre-IND update

· Issued by AdAlta Ltd. via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

This designation provides AdAlta with significant regulatory advantages, including market exclusivity and financial incentives for development. The pre-IND meeting confirmed the potential to utilize existing preclinical and clinical data for the IND submission, supporting the company's clinical trial preparations in Australia.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement | 17 November 2026 AdAlta Limited (ASX:1AD) US FDA Orphan Drug Designation for EW-001 in mesothelioma assigned to AdAlta AdAlta now holds a valuable US regulatory asset for its lead CAR-T therapy, following its first pre-IND meeting with the FDA Investment highlights • The US...

AdAlta Ltd. on 6ix

Earlier from AdAlta

All AdAlta news releases